Mercer International Stock Discussion

Upgrades
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...

$Mercer International (MERC.US)$ The head of India's leading medical research institute said on Wednesday that Mercer's new oral crown drug molnupiravir has "significant safety issues" that may prevent it from joining the country's list of viral treatments.
The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.